LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer

BACKGROUND: Estrogen receptor-positive (ER+) breast cancers represent approximately two-thirds of all breast cancers and have a sustained risk of late disease recurrence. Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors have shown significant efficacy in ER+ breast cancer. However, their effects...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Xi, Ge, Li-Ping, Li, Da-Qiang, Shao, Zhi-Ming, Di, Gen-Hong, Xu, Xiao-En, Jiang, Yi-Zhou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212688/
https://www.ncbi.nlm.nih.gov/pubmed/32393270
http://dx.doi.org/10.1186/s12943-020-01210-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212688/
https://www.ncbi.nlm.nih.gov/pubmed/32393270
http://dx.doi.org/10.1186/s12943-020-01210-9

Ejemplares similares